

# BUILDING GENOMICS NETWORKS IN AFRICA

**Prof Tulio de Oliveira**  
for the **Network for Genomic Surveillance South Africa (NGS-SA)** and the  
**Africa CDC Pathogen Genomics Initiative (PGI)**



EDGEWOOD CAMPUS




HOWARD COLLEGE CAMPUS



NELSON R MANDELA SCHOOL OF MEDICINE



PIETERMARITZBURG CAMPUS



WESTVILLE CAMPUS

# Presentation




Network for Genomic Surveillance in South Africa



Africa CDC Pathogen Genomics Initiative (PGI) to expand surveillance to Africa.

# Network for Genomic Surveillance in South Africa (NGS-SA)




Supported by the DSI and the SA MRC  
Msomi N, Mlisana K, *et al.* Lancet Microbe 2020




# Introductions and local transmission of SARS-CoV-2 (first wave)


**A** Epidemic and genomic data in South Africa



**B** Introduction into South Africa




**C** Sampling in South Africa



Tegally, Wilkinson et al. *Nature Medicine* 2021




# Distribution of SARS-CoV-2 lineages South Africa



Data from **3324 sequences** from all 9 provinces, collected up to 19 Jan

Tegally, Wilkinson, Giovanetti, et al. *Nature* 2021 (in press)

# Genomic map of 501Y.V2 (B.1.351, 20H)



Three mutations in spike receptor-binding domain & cluster of mutations in N-terminal domain

Tegally, Wilkinson, Giovanetti, et al. *Nature* 2021 (in press)

COMMENT | ONLINE FIRST

# A genomics network established to respond rapidly to public health threats in South Africa

Nokukhanya Msomi • Koleka Mlisana • Tulio de Oliveira ✉

on behalf of the Network for Genomic Surveillance in South Africa writing group † • Show footnotes

Open Access • Published: August 18, 2020 • DOI: [https://doi.org/10.1016/S2666-5247\(20\)30116-6](https://doi.org/10.1016/S2666-5247(20)30116-6)

## ALARMING COVID VARIANTS SHOW KEY ROLE OF GENOMIC SURVEILLANCE

Efforts to track SARS-CoV-2 sequences have helped to identify worrying lineages – but researchers are blind to emerging mutations in some regions.

By David Cyranoski

Already, 2021 is shaping up to be the year of COVID-19 variants. In the past two months, scientists have identified several fast-spreading viral variants that have prompted government restrictions in many countries – and new lineages are being detected more frequently.

The pandemic has ushered in an era of genomic surveillance in which scientists are tracking genomic changes to a virus at a speed and scale never seen before. But surveillance is patchy globally, particularly in the United

States, which has the world's largest COVID-19 outbreak, and in many low- and middle-income countries. Scientists warn that worrying variants are probably spreading undetected in these regions.

"Genomic epidemiology has come of age during this pandemic," says Oliver Pybus, who studies infectious-disease evolution at the University of Oxford, UK. The field has transformed from a "theoretical backwater" to a tool that helps drive public-health decision-making quickly, he says. But to be as effective as possible, surveillance needs to be widespread, standardized and embedded in

national pandemic-prevention programmes, scientists say.

### Surveillance networks

The key to good surveillance is the sequencing and sharing of enough genomes to track mutations and variants of concern as they arise. In the past year, more than 360,000 SARS-CoV-2 genomes have been sequenced and stored on GISAID, a non-profit online database for sharing viral genomes. Geographical distribution of the sequences on GISAID is broad, covering more than 140 countries. But most countries have uploaded only a small number

wouldn't be useful. "I don't care for the term PHEIC," says Alexandra Phelan, a global-health lawyer at Georgetown University in Washington DC, "but I worry that if we get too into the words, we miss the point that countries need to act appropriately when there is a declaration."

Global-health scholars question why a PHEIC for COVID-19 wasn't declared sooner. On 22 January 2020, Tedros convened a closed-door meeting of virologists, public-health researchers and certain government representatives – as the PHEIC process dictates. They decided that a warning wasn't warranted, but a week later, the committee flipped its position. The delay might have cost the world time to contain the virus.

Still, a one-week lag in declaring a global emergency isn't even the most concerning action that took place in the early days of the COVID-19 pandemic, critics say. When Tedros declared the PHEIC, he advised governments to move fast with public-health measures including tests and social distancing. He also asked them to resist bans on travel and trade because, historically, they had been of limited utility and are potentially harmful.

## FAST-SPREADING COVID VARIANT CAN ELUDE IMMUNE RESPONSES

Early studies find that a variant of the virus identified in South Africa could compromise immunity.

By Ewen Callaway

Evidence is growing that some coronavirus variants could evade immune responses triggered by vaccines and previous infections. Researchers are trying to make sense of a tsunami of laboratory studies released last week that raise concerns about some emerging variants and mutations.


"Some of the data I've seen have really scared me," says Daniel Altmann, an immunologist at Imperial College London, who worries that

some of the results could portend a reduction in the effectiveness of COVID-19 vaccines.

But the picture is murky, Altmann and other scientists emphasize. The studies – which examined the blood of small numbers of people who had recovered from COVID-19 or received a vaccine – probed only their antibodies' capacity to 'neutralize' variants in laboratory tests, and not the wider effects of other components of their immune response.

Neither do the studies indicate whether the changes in antibody activity make any difference to the real-world effectiveness of



# Triple RBD mutant and 501Y.V2 resistant to “class 1” mAbs



Wibmer et al, 2021 (Nature Medicine in review)




# Loss of neutralization with 501Y.V2 (Live Virus)



**D**  $IC_{50}$

Plasma donor:	1st wave	501Y.V2	Ratio
039-13-0013	0.004312	KO	ND
039-02-0014	0.001691	0.3454	204.3
039-02-0015	0.001158	0.06167	53.23
039-13-0017	0.001567	0.05978	38.13
039-13-0033	0.001113	0.01083	9.589
039-13-0062	0.003114	0.01768	5.677







Cele et al. Nature 2021 (in review)

# Sensitivity of 501Y.V2 to plasma from ChAdOx vaccinees

PSVN: Penny Moore

LVN: Alex Sigal



Titre >400 50-399 <50

Madhi NEJM 2021 (in review)

### Sharp split on Trump trial

UC poll finds wide divisions in California about ex-president's role in Capitol riot.

By DAVID LAUTER

WASHINGTON — Less than five weeks after his riotous supporters stormed the Capitol, Donald Trump is set to go on trial a second time in the Senate — an impeachment proceeding that will give the public the fullest accounting as far as the former president's role in the attack that almost surely will resolve a divided nation's view of his legacy.

The poll remains stark nationally and in California, where a new poll finds that more than 6 in 10 Democrats, but fewer than 2 in 10 Republicans, say they believe Trump was a major contributor to the insurrection.

Only 16% of California Republicans favor a Senate conviction of Trump, compared with 92% of the state's Democrats, according to the poll released Monday by UC Berkeley's Institute of Government Studies.

Republicans, however, have their own internal divisions over the former president, with a significant majority viewing him at least partially culpable and rejecting him as a continuing leader for their party.

Similar divides show up in polls nationwide and in comments by Republican

(See 'Deal,' A5)

### Divide in GOP hits California lawmakers

By MELANIE MASON

Nearly a month after objecting to electoral votes cast for President Biden, Rep. Mike Garcia wanted to clear the air.

In a lengthy Jan. 30 op-ed in a local newspaper, Garcia, Republican and former Navy fighter jet pilot, denounced the blowback on social media that branded him a "traitor," a "liar," a "traitor," or even worse.

Roughly 30 miles to the north, Rep. David Valadao also had some explaining to do after voting to impeach President Trump for his part in inciting the riot at the U.S. Capitol. He, like Garcia, was disgraced by some constituents as a traitor.

Two votes in Congress to certify Biden's election and another to impeach the president — spurred the two California Republicans into the pitched battle over the future of their party.

Whether the GOP will demonstrate allegiance to Trump or break from his influence. On one side at Garcia and most House Republicans (See Republicans, A5)



THE MAGNIFICENT SEVENTH

Tampa Bay's Tom Brady, right, and Rob Gronkowski are jubilant after their Buccaneers defeated the Kansas City Chiefs 31-9 in Super Bowl LV. It was MVP Brady's seventh championship. **SPORTS, D1**

### Legacy of Tuskegee: Distrust

Recalling syphilis study, Black Alabamians wary of vaccine

By KURTIS LEE



A MAN in given medical treatment in a field. The U.S. government launched a syphilis study in Tuskegee and Mason County, Ala.



OMAR NEAL'S uncle, Freddie Lee Tyson, was a victim of the study that enrolled Black men under false pretenses starting in the 1930s.

**GAINS IN L.A.:** As virus rates continue to fall, variants and Super Bowl parties pose a risk. **CALIFORNIA, B1**

### S. Africa's vaccination plans upended

By MELISSA HEAVY AND EMILIE BAUMGAERTNER

The coronavirus strain fueling a resurgence of COVID-19 in South Africa was not allowed down by a vaccine that officials had been counting on to protect its front-line healthcare workers, prompting the im-

plementation to shelve plans for an inoculation campaign that would have begun this month.

"We have decided to put a temporary hold on the rollout of the vaccine," Dr. Zwane Mkhize, South Africa's health minister, said Sunday. "More work needs to be done."

The experimental vaccine, developed by AstraZeneca and Oxford University, seemed promising just a few months ago.

"We have decided to put a temporary hold on the rollout of the vaccine," Dr. Zwane Mkhize, South Africa's health minister, said Sunday. "More work needs to be done."

tion, developed by AstraZeneca and Oxford University, seemed promising just a few months ago.

"We have decided to put a temporary hold on the rollout of the vaccine," Dr. Zwane Mkhize, South Africa's health minister, said Sunday. "More work needs to be done."

### Virus inflicts sticker shock

Some patients have out-of-pocket costs waived, but others run into confusing policies and crushing bills.

By MARIA L. LA GANZA

VACAVILLE, Calif. — It was bad enough that Patricia Navarro's husband rushed her to the emergency room on his birthday and didn't see her again for nearly a month.

That she was transferred to the intensive care unit in a different hospital, one that could better care for her deteriorating condition, and that her husband had no idea where she was or even how to find her.

That her doctor called him two days later to break the news: His wife, the physician said, had less than a 10% chance of surviving COVID-19.

Then the hereditary illness began to arrive. The grand total to settle the 54-year-old woman's bill: \$1,338,084.

That's the average cost — with five jobs and nine months' worth of insurance between them — are actually on the hook for \$42,384.20.

The oldest that they will pay it off zero.

The most serious cases of COVID-19 don't just attack a patient's lungs, leading to pneumonia, respiratory failure, septic shock, blood clots, brain fog and more than 460,000 deaths in the U.S. to date. They can also damage a virus victim's bank account.

Because, while it is difficult to know who will die from the virus and who will

(See Bills, A9)



Ex-Secretary of State Shaula Dies

Influential Cabinet official in Reagan and Nixon administrations shaped U.S. foreign policy. **OBITUARY, A1**

**Will Biden push for electric cars?**

California's plan to ban gas-powered cars by 2035 could become the U.S. model. **NEWS, A1**

**COVID deepens Mexico's despair**

Hospitals overflow and oxygen tanks are scarce as the vaccine rollout stalls. **WORLD, A1**

**Washer Party among L.A. Buns '21, '23**

But that was before the emergence of a coronavirus who received a \$1.338 billion. **THE GOVERNMENT ORIGIN, A1**

### Variant-proof vaccines — invest now for the next pandemic

COVID's evolution signals the importance of rational vaccine design based on broadly neutralizing antibodies.



### Science

Contents News Careers Journals

SHARE



A participant in the South African trial of the AstraZeneca–University of Oxford COVID-19 vaccine has blood drawn before receiving her second dose. **AP PHOTO/JEROME DELAY**

### South Africa suspends use of AstraZeneca's COVID-19 vaccine after it fails to clearly stop virus variant

By Jon Cohen | Feb. 8, 2021, 2:15 PM

**BUSINESS INSIDE:** Biden inherits ambiguous regulations for driver-assist technology. **A10**

# Conclusion I:


- Genomic surveillance is a critical component of the epidemic response – exemplified by early detection, characterization and tracking of this new 501Y.V2 variant within and outside South Africa
- We detected a new lineage with multiple mutations at key sites in spike protein which decrease neutralization of antibodies.
- Variant decrease efficacy of certain vaccines.

---

# **Accelerating SARS-CoV-2 Sequencing in Africa**

COMMENT | ONLINE FIRST

# Accelerating genomics-based surveillance for COVID-19 response in Africa

Sofonias K Tessema • Seth C Inzaule • Alan Christoffels • Yenew Kebede • Tulio de Oliveira • Ahmed E Ogwel Ouma • Christian T Happi • John N Nkengasong  • Show less

**Open Access** • Published: August 18, 2020 • DOI: [https://doi.org/10.1016/S2666-5247\(20\)30117-8](https://doi.org/10.1016/S2666-5247(20)30117-8)

## Africa's \$100-million Pathogen Genomics Initiative

On Oct 12, 2020, the Africa Centres for Disease Control and Prevention (CDC) secured US\$100 million for pathogen genomics research and development through a partnership, the Africa Pathogen Genomics Initiative (PGI), expected to transform disease surveillance on the continent and is now preparing to start running programmes in 2021.

Africa PGI is a 4-year collaboration between the Africa CDC Institute of Pathogen Genomics, US CDC, the Bill & Melinda Gates Foundation, software giant Microsoft, genomics sequencing technology company Illumina, and UK-

of high-impact applications, and the integration of pathogen genomics into the existing disease surveillance system are required, he said.

Africa PGI is building a pan-African disease surveillance and laboratory network based on pathogen genomic sequencing to identify and inform research and public health responses to COVID-19 as well as other epidemic threats and endemic diseases such as AIDS, tuberculosis, malaria, cholera, and other infectious diseases. "Africa is one continent beaten by many pathogens and pandemics", Tulio de Oliveira, director of the KwaZulu-Natal

An African-owned data library and real-time data-sharing platform will be established to support the laboratory network, in alignment with different African Union member states' regulations.

At the initiative's onset, 72% of Africa's genome sequencing capacity is concentrated in four countries: South Africa has 50 institutions, Kenya 20, Nigeria ten, and Morocco five. According to Africa CDC, about 83% of these are in non-public health institutions. A few African countries have a single, privately owned, genomic sequencing institution.



For more on Africa PGI see <https://africacdc.org/download/africa-pathogen-genomics-initiative-factsheet/>

For more on Network for Genomic Surveillance see **Comment** *Lancet Microbe* 2020; **1**: e299–30

# ACCELERATING SARS-COV-2 SEQUENCING IN AFRICA

**Coordination**


**Operationalization of the network**

**Leverage on existing capacity**

Specialized Genomics and Bioinformatics Centers (SGBC)


Regional COVID-19 Sequencing Laboratories

National COVID-19 Sequencing Laboratories



**Access to sequencing facility**


# ACCELERATING SARS-COV-2 SEQUENCING IN AFRICA



1. Mobilize resources and leverage on existing capacity
2. Start simple and establish routine surveillance
3. Support sample collection and shipment logistics
4. Support sequencing – reagents, equipment upgrades, and personnel
5. Support data analysis, sharing, and interpretation



# Sampling and sequencing



Due to various reasons not all African sequences are sufficient for analyses (i.e. too short, clustered SNPs or high number of SNPs). These need to be removed prior to phylogenetic analyses.


Done in *NextClade*

<https://clades.nextstrain.org>

# Sampling and sequencing


Genomic data from SARS-CoV-2 sequencing in Africa.

5438 good quality African sequences for analyses.



# 501Y.V2 in Mozambique

## Data from Instituto Nacional de Saúde (INS)



# ACCELERATING SARS-COV-2 SEQUENCING IN AFRICA

## Current challenges

- 1. Lack of standardized sampling framework tailored to the African setting (what to sequence?)**
- 2. Market and custom issues on the timely availability of reagents**
- 3. Material Transfer Agreements and import permits**
- 4. Standardized data analysis, sharing, and reporting frameworks**



Jun 17, 2020

★ Bookmark

Run

Copy / Fork

## 🌐 Illumina Nextera DNA Flex library construction and sequencing for SARS-CoV-2: Adapting COVID-19 ARTIC protocol ▼

Sureshnee Pillay<sup>1</sup>, Jennifer Giandhari<sup>1</sup>, Houriiyah Tegally<sup>1</sup>, Eduan Wilkinson<sup>1</sup>, Benjamin Chimukangara<sup>1</sup>, Richard Lessells<sup>1,2</sup>, Yunus Moosa<sup>2</sup>, Inbal Gazy<sup>1</sup>, Maryam Fish<sup>1</sup>, Lavanya Singh<sup>1</sup>, Khulekani Sedwell Khanyile<sup>1</sup>, Vagner Fonseca<sup>1,3,4</sup>, Marta Giovanetti<sup>4</sup>, Luiz Carols Alcantara<sup>3,4</sup>, Tulio de Oliveira<sup>1,5,6</sup>,

<sup>1</sup>KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa;

<sup>2</sup>Infectious Diseases Department, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa;

<sup>3</sup>Laboratorio de Genetica Celular e Molecular, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil;

<sup>4</sup>Laboratório de Flavivírus, Instituto Oswaldo Cruz Fiocruz, Rio de Janeiro, Brazil;

<sup>5</sup>Centre for Aids Programme of Research in South Africa (CAPRISA), Durban, South Africa;

<sup>6</sup>Department of Global Health, University of Washington, Seattle, Washington, USA

2

Works for me

[dx.doi.org/10.17504/protocols.io.bhjjg4jw](https://dx.doi.org/10.17504/protocols.io.bhjjg4jw)

Coronavirus Method Development Community


KRISP



Jennifer Giandhari



# Assembly Automation – Illumina, S5lon and Nanopore




# Data is only analyzed when in GISAID!

## In Focus

### 41,000 viral genomic sequences of hCoV-19 shared with unprecedented speed via GISAID

Since the start of the COVID-19 outbreak and the identification of the pandemic virus, laboratories around the world are generating viral genome sequence data with unprecedented speed, enabling real-time progress in the understanding of the new disease and in the research and development of candidate medical countermeasures. Sequence data are essential to design and evaluate diagnostic tests, to track and trace the ongoing outbreak, and to identify potential intervention options. [Listen to PRI's Elana Gordon.](#)

GISAID data Submitters and Curators ensure real-time data sharing of hCoV-19 remains reliable, to enable rapid progress in the understanding of the new COVID-19 disease and in the research and development of candidate medical countermeasures.



## EpiCoV Data Curation Team



**Aengus Stewart**

The Francis Crick Institute, London

**Sheila Ons**

Universidad Nacional de La Plata, Buenos Aires

**Thomas Bigot**

CNRS & Institut Pasteur, Paris

**Daniel See Rui En**

Bioinformatics Institute Singapore A\*Star

## Recent hCoV-19 data submissions

[hCoV-19/Russia/CRIE162784/2020](#)

[hCoV-19/Bangladesh/BCSIR-NILMRC\\_050/2020](#)

[hCoV-19/Singapore/323/2020](#)

[hCoV-19/England/SHEF-D3464/2020](#)

[hCoV-19/USA/WA-UW-10138/2020](#)

Number of hCoV-19 genomic sequences: 41,735

# Webinar Series on COVID-19 Genomic Surveillance in Africa /Technical Session/

## SARS-CoV-2 whole genome sequencing and quality control



**Dr. Jennifer  
Giandhari**



**Sureshnee  
Pillay**



**Houriiyah  
Tegally**



**Emmanuel  
James San**



**Wednesday, 05 August 2020  
2:00PM - 3:00PM East Africa Time**

**TO REGISTER VISIT: <https://bit.ly/2Okfoqy>**

Organized by:



In partnership with:



Weekly Seminar Series

UKZN INSPIRING GREATNESS



# Acknowledgements

## **KRISP at UKZN:**

Houriayah Tegally  
Eduan Wilkinson  
Jennifer Giandhari  
Sureshnee Pillay  
Emmanuel James San

## **NHLS and NICD:**

Koleka Mlisana  
Nokukhanya Msomi  
Jinal N. Bhiman  
Anne von Gottberg  
Kurt Wibmer  
Sibongile Walaza  
Mushal Allam  
Arshad Ismail  
Allison J. Glass  
Penny Moore

## **NHLS - Stellenbosch**

Susan Engelbrecht  
Gert Van Zyl  
Wolfgang Preiser

## **NHLS – UCT**

Carolyn Williamson  
Diana Hardie  
Nei-yuan Hsiao  
Darren Martin  
Arash Iranzadeh

## **NHLS – UFS**

Dominique Goedhals  
Martin Nyaga

## **AHRI**

Alex Sigal  
Sandile Cele  
Willem Hanekom

## **CAPRISA**

Salim Abdool Karim

## **UKZN - Big Data**

Francesco Petruccione  
Ilya Sinayskiy

## **University of Oxford**

José Lourenço

## **FioCruz, Brazil**

Vagner Fonseca  
Marta Giovanetti  
Luiz Carlos Junior  
Alcantara

## **Africa CDC**

John Nkengasong  
Sofonias Tessema

## **Netcare:**

Richard Friedland  
Craig Murphy  
Caroline Maslo  
Liza Sitharam

## **DSI**

Glaudina Loots

## **SA MRC**

Glenda Gray